Advanced Search

Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2010 June;35(2) > Minerva Endocrinologica 2010 June;35(2):61-72

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

 

Minerva Endocrinologica 2010 June;35(2):61-72

STEROIDS AND BEYOND 

 REVIEWS

Management of steroid replacement in adrenal insufficiency

Koetz K., Kienitz T., Quinkler M.

Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Berlin, Germany

Adrenal insufficiency is caused by either primary adrenal failure, mostly due to autoimmune adrenalitis, or by hypothalamic-pituitary impairment of the corticotropic axis, predominantly by long-term pharmacodynamic glucocorticoid treatment or by pituitary tumour growth and related treatment. Despite optimized life-saving glucocorticoid and mineralocorticoid replacement therapy, health-related quality of life in adrenal insufficiency is more severely impaired than previously thought and patients with adrenal insufficiency are also threatened by an increased mortality. Optimizing hormone replacement remains one of the most challenging tasks in endocrinology. Monitoring of glucocorticoid replacement quality is hampered by lack of objective assessment tools and therefore largely based on clinical grounds. Thus, long-term management of patients with adrenal insufficiency remains a continuous challenge asking for the experienced specialist. However, diagnosis and management of suspected acute adrenal failure is an important task for all physicians. This review explains the rationale behind the current hormone replacement scheme, points to the deficits and hints at possible future therapies.

language: English


FULL TEXT  REPRINTS

top of page